NCT02275533 2026-03-19
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT02397720 2025-06-08
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03417154 2023-05-26
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT04913922 2022-11-08
AARON
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT04044209 2022-01-20
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
Phase 2 Withdrawn
NCT03381118 2019-04-05
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
St. Petersburg State Pavlov Medical University
Phase 2 Terminated